Percutaneous closure of secundum XXXX in adults a single center experience with the amplatzer septal occluder.

@entity1 @entity120 @entity1031 @entity118 @entity943
Percutaneous closure of @entity118 ( @entity118 ) is increasingly performed in pediatric and adult @entity1 . This study reports a single-center experience with the use of the Amplatzer Septal Occluder for percutaneous @entity118 closure in adults. One hundred and seventeen consecutive @entity1 were prospectively included in the database. The procedure was successful in 106 @entity1 (90.6%). The mean age was 50 years. Eighty-four percent of the @entity1 had a Qp:Qs > 1.5. Other indications included a history of @entity1031 , decreased exercise tolerance, @entity943 , evidence of @entity120 or right heart overload. Mean procedure time was 44 minutes, and mean fluoroscopy time was 13 minutes. The mean defect diameter was 17.2 mm (range, 5 30 mm). There was no residual shunting at the end of the procedure in 75% of the @entity1 . Shunting was minimal in all but 2 of the remaining 25 @entity1 (1.8%). No major complications were observed at a mean follow-up of 19 months. @entity1 in whom the procedure failed had larger defects (mean, 25.0 mm versus 18.3 mm; p < 0.001), larger right ventricles (44.1 mm versus 38.2 mm; p = 0.03) and more significant shunting (Qp:Qs, 3.5 versus 2.1; p < 0.001). New York Heart Association functional class improved in all but 1 @entity1 . Percutaneous @entity118 closure using ASO is safe and mid-term results compare favorably with those reported with surgical @entity118 closure. It can therefore be recommended as the first line of treatment in adult @entity1 with secundum @entity118 .
